OKYO Pharma (OKYO) Announces 35K Share Insider Buy by Chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- Wall St futures inch higher as chips extend gains
- Oil falls as investors await clarity after Iran-Israel halt attacks
- Tech stocks gain as Trump mulls government stake in AI companies
- Morgan Stanley’s Wilson calls Friday U.S. selloff a "healthy reset"
- Hedge funds loaded up on equities ahead of sharp Friday drop
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Salesforce to acquire metering platform M3TER for consumption billing
- Quantum Space to go public via $1.2B SPAC merger
- SpaceX sets $135 price for blockbuster IPO, upending Wall Street convention
OKYO Pharma Announces Chairman Acquires Shares
August 21, 2024 7:00 AM EDTLONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial... More
